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Gavin J Becker, MD, FRACP (Work Group Co-Chair), is
Professor and Director of Nephrology at the Royal
Melbourne Hospital and Clinical Director of Renal and
Endocrinology Services at Melbourne Health. He maintains
an active role in numerous professional societies including
serving as a current member of the International Society of
Nephrology (ISN) Executive Committee, Cochrane Renal
Collaboration Advisory Board and Co-Chair of the World
Health Organization ICD-11Renal Diseases Working Group.
He is a Past President of the Asian Pacific Society of
Nephrology. Dr Becker has published over 300 papers,
chapters and books and presently serves as Associate Editor
for Nephrology Dialysis Transplantation. He has served as
Editor of Nephrology, Associate Editor or on the editorial
boards of the Journal of the American Society of Nephrology,
Clinical Journal of the American Society of Nephrology,
American Journal of Kidney Diseases, Nephron, and Journal of
Nephrology. His research interests center on the progression
of kidney failure, development of guidelines for renal care,
promotion of renal physician education and the development
of nephrology in the Asian Pacific region. In recognition for
his work, he was awarded the International Distinguished
Medal by the US National Kidney Foundation in 2002. He
was also a recipient of an Honorary Fellowship of the Ceylon
College of Physicians in 2003, the Oshima Award from the
Asian Pacific Society of Nephrology in 2005 and Chairman’s
‘Best of Health’ Award from Melbourne Health in 2002 and
again in 2009.
Dr Becker reported no relevant financial relationships
David C Wheeler, MD, FRCP (Work Group Co-Chair),
holds an academic position in Nephrology (Reader) at
University College London, UK and is an Honorary
Consultant Nephrologist at the Royal Free Hospital. His
research is focused on the cardiovascular complications of
CKD and the role of vascular risk factors in progression of
kidney damage. Dr Wheeler is a member of the International
Steering Committee of the Study of Heart and Renal
Protection (SHARP) and was UK National Coordinator for
the trial. He is involved in several other randomized trials and
observational studies involving patients with CKD.
Dr Wheeler is Co-Chair of KDIGO, having served
previously on its Executive Committee and Board. He
received an International Distinguished Medal from the US
National Kidney Foundation in recognition of his contribu-
tion to guideline development. In the UK, he has been elected
President of the Renal Association for the term 2012–2014.
Dr Wheeler has served on the editorial boards of American
Journal of Kidney Diseases and Journal of the American Society
of Nephrology and is presently Co-Editor for Nephrology
Dialysis Transplantation.
Advisor/Consultant: Amgen
Honoraria: Abbott; Amgen; Fresenius; Otsuka; Shire
Travel Stipend: Amgen; Merck Sharp & Dohme; Shire
Grant/Research Support: Abbott; Genzyme
Dick de Zeeuw, MD, PhD, earned his MD from the
University of Groningen in 1975. He completed his PhD
thesis in 1980 on the topic of renal hypertension at the Renal
Department of the Groningen University. He later obtained
training in clinical and experimental renal research at the
Renal Department in Groningen and clinical pharmacology
at the University of Dallas (1984–1985) and was board
certified in 1996 at the University of Groningen. Dr de Zeeuw
is currently Professor and Chair of the Department of
Clinical Pharmacology with a joint appointment in the
Department of Nephrology. He has served on the editorial
board of several international journals, including Clinical
Nephrology, Current Opinion in Nephrology and Hypertension,
Journal of Geriatric Urology and Nephrology, Journal of
Hypertension, Journal of the Renin-Angiotensin-Aldosterone
System, Kidney International, NDT Plus, and Nephron.
Dr de Zeeuw is Director of the Groningen University
Institute for Drug Exploration (GUIDE), and member of ISN
Council. His research interests include: optimizing current
therapies and finding new therapeutical approaches to reduce
the progressive loss of cardiovascular and renal function,
both in diabetic and non-diabetic renal disease. The role of
albuminuria/proteinuria and microalbuminuria as biomar-
kers for cardiac and renal disease progression has been his
particular interest, not only in trying to establish the
independent ‘causal’ role of albumin leakage in renal and
CVD progression, but also to establish intervention strategies
that lower albuminuria/proteinuria with the supposed organ
protective results. In his ‘albuminuria’ quest he initiated large
cohort studies such as PREVEND (in general population)
and GIANTT (type 2 diabetes), and is involved in the
leadership of several clinical trials on preventing diabetic car-
diovascular and renal disease progression such as RENAAL
(angiotensin II receptor antagonist), PLANET (statin),
TREAT (darbepoetin), VITAL (vitamin D), SUN (sulodex-
ide), ALTITUDE (renin-inhibition), CANVAS (SGLT2-in-
hibition), RADAR (atrasentan) and BEACON (bardoxolone).
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Unraveling the reasons for individual therapy resistance
and creating a response score to evaluate the total effect of
drugs are the topics that he judges to be of important focus
for the next decade. He has authored more than 440
international scientific publications and more than 60 book
chapters, and received the Lennart Hansson Memorial
Lecture Award from the European Society of Hypertension,
the International Distinguished Medal from the US National
Kidney Foundation, and a special lecture award from the
Japanese Society of Nephrology.
Advisor/Consultant: Abbott; Amgen; Astellas; AstraZeneca;
Bristol-Myers Squibb; HemoCue; Johnson & Johnson; Merck
Sharp & Dohme; Novartis; Reata; Takeda; Vitae
Toshiro Fujita, MD, is Professor and Chairman of the
Department of Internal Medicine and Chief of the Depart-
ment of Nephrology and Endocrinology at the University of
Tokyo. He qualified in medicine in 1972 at the Keio
University School of Medicine, Japan and remained in Keio
until 1976, during which time he completed his medical
internship and residency. Between 1976 and 1978, he was a
Research and Clinical Fellow at National Heart, Lung, and
Blood Institute, Bethesda, Maryland, USA. Upon his return
to Japan, he was appointed Assistant Professor of Internal
Medicine, firstly at the University of Tsukuba and later at the
University of Tokyo School of Medicine. Since 1995,
Professor Fujita has been Chairman of the Department of
Internal Medicine at the Graduate School of Medicine and
Faculty of Medicine, University of Tokyo, and is Chief of
the Department of Nephrology and Endocrinology at the
University of Tokyo Hospital.
In 1980, Fujita and Bartter at NIH demonstrated the
pathophysiology of salt-sensitive hypertension (Am J Med
1980). Since then, he has been continuing research on renal
and metabolic aspects of hypertension. His research interests
include nephrology, endocrinology, metabolic science and
cardioangiology. Dr Fujita’s group has reported the involve-
ment of aldosterone/mineralocorticoid receptor (MR) activa-
tion in salt-sensitive hypertension and metabolic syndrome.
Recently, they found an alternative pathway of MR activation:
modification of MR function by Rac1 GTPase (Nat Med
2008). Most recently, his group clarified the involvement of
aberrant renal b adrenergic receptor-WNK4 pathway in salt-
induced hypertension (Nat Med 2011).
A renowned expert in his field, Professor Fujita has been
actively contributing to professional associations and scien-
tific publications and his contribution to the study of
hypertension and kidney diseases has been widely recognized.
In 2009, Professor Fujita was awarded Arthur Corcoran
Lecture Award by the Council for High Blood Pressure
Research, American Heart Association (AHA). Over the past
30 years, Professor Fujita has published over 500 scientific
articles and has been a member of the Committee of the High
Blood Pressure Council, AHA. Professor Fujita is currently
serving as a Consulting Editor for Hypertension and an
Editorial Board member for Diabetes. He was Past President
of the Japanese Society of Hypertension (2003–2005), the
Japanese Society of Internal Medicine (2004–2006), the Japanese
Society of Endocrinology (2006–2007), and the Japanese
Society of Nephrology (2009–2010). He was also Vice-President,
International Society of Hypertension (2008–2010).
Speaker: Astellas; Boehringer Ingelheim; Daiichi Sankyo;
Merck; Mitsubishi Tanabe; Mochida; Novartis; Pfizer; Takeda
Grant/Research Support: Astellas; Boehringer Ingelheim;
Daiichi Sankyo; Merck; Mitsubishi Tanabe; Mochida;
Novartis; Pfizer; Takeda
Susan L Furth, MD, PhD, is Chief, Divison of Pediatric
Nephrology at Children’s Hospital of Philadelphia and
Professor, Department of Pediatrics and Epidemiology,
Perelman School of Medicine at University of Pennsylvania
School of Medicine, where she is also currently a Senior
Scholar and faculty member at the institution’s Center for
Clinical Epidemiology and Biostatistics. Dr Furth received
her medical degree from University of Pennsylvania and
doctorate degree from Johns Hopkins University School of
Hygiene and Public Health. She maintains a longstanding
interest in the studies of children and adolescents with kidney
disease, particularly their risk factors and consequences,
including pediatric hypertension. As Principal Investigator of
CKiD, she directs a multidisciplinary team for one of the
largest multicenter, prospective cohort studies of children
with CKD to better identify risk factors for CKD progression,
neurocognitive deficits and CVD. Dr Furth is also a recipient
of an National Institute of Diabetes and Digestive and Kidney
Diseases Investigator Award in Clinical Research to mentor
fellows and junior faculty on the evaluation of hypertension
and risk of kidney dysfunction using national pediatric data.
In addition to being a peer reviewer for 20 academic
journals, Dr Furth has authored over 100 publications and
served as a thesis advisor to more than 30 students. As an
acknowledgment for her contribution, Dr Furth was awarded
‘Pediatric Leaders for the 21st Century’ by the American
Society of Pediatric Nephrology and American Academy of
Pediatrics and is currently President of the Society for
Pediatric Research.
Dr Furth reported no relevant financial relationships
Hallvard Holdaas, MD, PhD, is senior consultant in
Nephrology at Department of Transplant Medicine, Oslo
University Hospital, Rikshospitalet, Norway, where he also
received his training in transplant medicine. His primary
research interests are immunosuppression, dyslipidemia, and
CVD in renal transplant recipients. He was the principal
investigator in the ALERT trial (fluvastatin) and co-
investigator in the AURORA and SHARP trials.
Dr Holdaas is a member of numerous professional
organizations including American Society of Nephrology,
American Society of Transplantation, European Dialysis and
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Transplant Association and European Society for Organ
Transplantation. He has published more than 170 original
articles, reviews and book chapters in the fields of
nephrology, dialysis and transplantation.
Advisor/Consultant: Merck (Schering Plough); Novartis;
Speaker: AstraZeneca; Bristol-Myers Squibb; Novartis
Shanthi Mendis, MBBS, MD, FRCP, FACC, is Senior
Advisor for Cardiovascular Diseases and Coordinator,
Chronic Disease Prevention and Management at the World
Health Organization (WHO) in Geneva, Switzerland. Prior
to taking up the position in WHO, she was Professor of
Medicine at Peradeniya Medical School in Sri Lanka from
1991–2000. As a specialist in cardiology and public health
with expertise in policy development, she has written
extensively on the prevention and management of CVD in
a global context. In particular, she has advocated for the
development of national policies and strategies to combat
non-communicable diseases which strike disproportionately
in low- and middle-income countries.
Dr Mendis reported no relevant financial relationships
Suzanne Oparil, MD, is Professor of Medicine, Professor of
Cell, Developmental and Integrative Biology, and Physiology
& Biophysics, and Director of the Vascular Biology and
Hypertension Program of the Division of Cardiovascular
Disease, Department of Medicine, University of Alabama at
Birmingham. She earned her medical degree at Columbia
University College of Physicians and Surgeons, New York and
completed her medical residency at Columbia Presbyterian
Hospital and cardiology fellowship at Massachusetts General
Hospital. Dr Oparil is Past President of the American Heart
Association (AHA) and American Society of Hypertension,
and a member of numerous editorial boards, societies and
important advisory positions with the NIH (Co-Chair, JNC
8). She has published over 700 journal articles, books, and
book chapters on topics in clinical cardiology, vascular
biology and hypertension. Dr Oparil has received a number
of honorary memberships, lectureships, and distinguished
awards for her contributions to hypertension research,
including the Irving Page-Alva Bradley Lifetime Achievement
Award, given by the AHA Council for High Blood Pressure
Research (2002); the 2008 Harriet Dustan Award, sponsored
by the AHA Council for High Blood Pressure Research; the
Virginia Frantz ‘22 Award for Distinguished Women in
Medicine (2010) presented by Columbia University College
of Physicians and Surgeons; and the ICS Distinguished
Lecture Award (2011), sponsored by the Institute of
Cardiovascular Sciences.
Dr Oparil is a cardiologist with a special interest in the
fundamental mechanisms of CVD and in applying this
information to the development of novel treatments. Her
research ranges from molecular and cellular studies to whole
animal studies to clinical trials. She has made a number of
innovative discoveries with major clinical impact: 1) observing
that angiotensin-converting enzyme (ACE) is involved in
vascular disease, leading to the development of ACE-Is;
2) identifying endothelin as the major mediator of pulmonary
hypertension and pulmonary vascular disease, leading to the
development of a class of drugs for patients with pulmonary
hypertension; and 3) defining novel pathways by which blood
vessels are protected from injury by estrogens, providing
crucial information on potential targets for future gene
therapy. She has made many significant contributions to
vascular biology and hypertension research.
Advisor/Consultant: BackBeat Medical; Bayer; Boehringer
Ingelheim; Daiichi Sankyo; Eli Lilly; Forest Laboratories;
Medtronic; Merck; NicOx; Novartis;Omron Healthcare; Pfizer
Grant/Research Support: Daiichi Sankyo; Merck; Novartis;
Takeda
Vlado Perkovic, MBBS, FRACP, FASN, PhD, is Executive
Director, George Clinical at The George Institute for
International Health and Staff Specialist in Nephrology and
Hypertension at the Royal North Shore and Sydney Adventist
Hospitals. Dr Perkovic received his medical and doctorate
degrees from University of Melbourne and completed his
training in nephrology and general medicine at the Royal
Melbourne Hospital. His research interests include elucidat-
ing the roles of BP and lipid management and their impact
on CVD in CKD patients. In this vein, Dr Perkovic is a
committee member of the ALTITUDE and SHARP trials and
an organizer of the Cardiovascular Guideline Group for
Caring for Australasians with Renal Impairment (CARI). As
an author of over 75 publications, Dr Perkovic also serves as a
peer reviewer to numerous journals and a grant reviewer for
the National Health and Medical Research Council.
Advisor/Consultant: Abbott; Baxter; Boehringer Ingelheim;
Johnson & Johnson; Vitae
Honoraria: AstraZeneca; Roche; Servier
Grant/Research Support: Baxter; Johnson & Johnson
Cibele Isaac Saad Rodrigues, MD, PhD, is a full Professor of
Nephrology at the Faculdade de Cieˆncias Me´dicas e da Sau´de –
Pontifı´cia Universidade Cato´lica de Sa˜o Paulo – (PUC-SP),
Brazil where she also graduated and completed her Residency
in Internal Medicine and Nephrology. She obtained her
master’s and doctorate degrees in Nephrology at the Federal
University of Sa˜o Paulo, Brazil. Currently she is the academic
coordinator of Santa Lucinda Hospital in Sorocaba–Sa˜o
Paulo, coordinator of the Hypertension Department of the
Brazilian Society of Nephrology, and member of the Scientific
Council of the Brazilian Society of Hypertension. From 2001
to 2009 she was the dean of the Centro de Cieˆncias Me´dicas e
Biolo´gicas (PUC-SP) and President of the Administration
Council of Santa Lucinda Hospital. Her primary research
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interests are hypertension, diabetic nephropathy and CKD.
Professor Rodrigues has published more than 40 journal
articles and contributed 15 book chapters in the field of
nephrology and hypertension. She is a member of numerous
professional organizations in Brazil and abroad, and has
served as peer reviewer for many scientific journals and an
advisory committee member to various organizations.
Dr Rodrigues reported no relevant financial relationships
Mark J Sarnak, MD, MS, is Professor of Medicine at Tufts
University of School of Medicine in Boston, Massachusetts,
USA and Director of Research in the Division of Nephrology
at Tufts Medical Center. He obtained his medical degree from
Columbia University College of Physicians and Surgeons and
master0s degree in clinical care research from Tufts University
of Medicine. His current research encompasses various topics
including the role of aging in CKD, the relationship between
cognition and CKD, and CVD in CKD. He has lectured
extensively on the epidemiology and management of
traditional and non-traditional cardiovascular risk factors
in CKD. Dr Sarnak has authored more than 175 publications
and is a peer reviewer for more than a dozen journals.
He was Co-Editor for American Journal of Kidney Disease
between 2006–2007 and presently serves on the Editorial
Board of the Annals of Internal Medicine. Among the recent
honors he has received include Best Teacher Award for the
Medical Residents in 2008, Excellence in Teaching in the
Medical Clerkship in 2009, and an acknowledgment in
Boston Magazine Best Doctors in both 2010 and 2011.
Dr Sarnak reported no relevant financial relationships
Guntram Schernthaner, MD, became Professor of Medicine
at the University of Vienna, Austria in 1987. Since 1988 he
has been Head of the Department of Medicine I at the
Rudolfstiftung Hospital in Vienna and between 1982 and
1988 he served as Head of the Division of Metabolism &
Endocrinology at the University of Vienna. Professor
Schernthaner’s main research interests are diabetes mellitus
(including diabetic nephropathy, diabetic retinopathy, insulin
resistance, CVD, hemostasis, immunotherapy of type 1 diabetes,
gestational diabetes), hypertension and morbid obesity.
Professor Schernthaner has held various prestigious
positions, including serving as Council Member and Vice-
President of the European Society for Clinical Investigation;
President of the Austrian Diabetes Association; President of
the first Joint Congress of the German and Austrian Diabetes
Associations; Council Member of the European Diabetes
Association; and President of the 32nd European Diabetes
Congress (EASD, Vienna 1996).
Professor Schernthaner has authored more than 350
publications in peer-reviewed journals and has presented
invited lectures at many international congresses, symposia
and universities in more than 50 countries. According to the
Citation Index of Web of Science his papers were cited 8300
times, with a Hirsch index of 43. He was also the principal
investigator of more than 40 studies (e.g., Canadian-
Cyclosporin Trial; Diapep277 Study; IDNT; IRMA 2;
QUARTET; PROactive; GUIDE; ORIGIN; LEAD-6; DIRECT;
EUREXA; DURATION; GENERATION).
Professor Schernthaner was awarded the Bertram Award
of the German Diabetes Association in 1982 and the Albert
Renold Medal of the European Association for the Study of
Diabetes in 1997. He is currently the Liaison Editor for
Diabetology for Nephrology Dialysis Transplantation.
Dr Schernthaner reported no relevant financial relationships
Charles R V Tomson, DM, FRCP, completed his under-
graduate studies at Cambridge University and attended
medical school at University of Oxford. Dr Tomson has
worked as a Consultant Nephrologist at Southmead Hospital
since April 1991. Between 1997 and 2004 he was course
director for the Renal Association’s Advanced Nephrology
Course, and between 1998 and 2002 he was Secretary of the
Renal Association’s Audit and Standards Subcommittee,
developing the 3rd edition of the Association’s Standards
document. In 2001 he set up and chaired the group that
developed the first UK guidelines on identification, manage-
ment and referral of patients with CKD. In 2004–5 he was a
Health Foundation Quality Improvement Fellow at the
Institute for Healthcare Improvement in Boston, USA. From
2006–2010 he was Chairman of the UK Renal Registry, which
measures and reports on the quality of care achieved by all
renal centers in the UK. He became President of the Renal
Association in May 2010.
Dr Tomson reported no relevant financial relationships
Carmine Zoccali, MD, is Director of the Division of
Nephrology, Hypertension and Renal Transplantation and
Chief of the Clinical Epidemiology of Renal Diseases and
Hypertension Unit of the National Research Council-IBIM
at Riuniti Hospital, Calabria. He is Professor of Nephrology
at the Postgraduate School of Nephrology, Universities
of Palermo and Messina, Sicily, Italy. Having trained in
medicine at the University of Rome, he completed specialist
training in renal diseases, hypertension, internal medicine
and clinical epidemiology.
Dr Zoccali’s research interests cover hypertension, cardio-
vascular complications in chronic renal failure, kidney disease
progression and the epidemiology of chronic renal failure.
He has contributed over 600 publications in these areas,
including more than 400 papers in international peer-
reviewed journals with a Hirsch index of 52.
Dr Zoccali founded NDT-Educational in 2004 and
directed its online educational resources between
2004–2009, and he is presently the Editor-in-Chief of
Nephrology Dialysis Transplantation. Dr Zoccali also holds
editorial positions in several national and international
nephrology journals including Clinical Nephrology, Clinical
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Journal of the American Society of Nephrology, Hypertension,
Journal of the American Society of Nephrology, Journal of
Hypertension, Journal of Nephrology, Kidney International,
Nephron Clinical Practice, and PlosOne. An ex-officio council
member of the European Renal Association–European
Dialysis and Transplant Association (ERA-EDTA), and of
their selection committee, he is a member of numerous other
nephrology societies. He was also Chairman of the European
Dialysis and Transplant Registry (2003–2009), President of
the Italian Society of Nephrology (2007–2008) and member
of the KDIGO Board of Directors.
Dr Zoccali reported no relevant financial relationships
KDIGO CHAIRS
Bertram L Kasiske, MD, is Professor of Medicine at the
University of Minnesota, USA. He received his medical
degree from the University of Iowa and completed his
Internal Medicine residency and fellowship training in
Nephrology at Hennepin County Medical Center where he
is currently Director of Nephrology.
Dr Kasiske is former Deputy Director of the United States
Renal Data System and former Editor-in-Chief of
American Journal of Kidney Diseases. He has served as
Secretary/Treasurer and on the Board of Directors of the
American Society of Transplantation, and on the Organ
Procurement and Transplantation Network/United Network
of Organ Sharing Board of Directors, and the Scientific
Advisory Board of the US National Kidney Foundation. He is
currently serving on the Board of Councilors of the
International Society of Nephrology. He is the Principal
Investigator for a National Institutes of Health-sponsored,
multi-center study of long term outcomes after kidney
donation and he is the Director of the Scientific Registry of
Transplant Recipients. He has over 160 scientific publications
in major peer reviewed journals, and 230 review articles,
editorials and textbook chapters. Dr Kasiske is also a recipient
of the US National Kidney Foundation’s Garabed Eknoyan
Award in 2003.
Advisor/Consultant: Litholink
Grant/Research Support: Bristol-Myers Squibb; Merck
(Schering Plough)
David C Wheeler, MD, FRCP (see biography earlier)
EVIDENCE REVIEW TEAM
Katrin Uhlig, MD, MS, is the Director, Guideline Develop-
ment at the Tufts Center for Kidney Disease Guideline
Development and Implementation, Boston, MA, Associate
Professor of Medicine at Tufts University School of Medicine,
and a staff nephrologist at Tufts Medical Center. Dr Uhlig
completed her training in internal medicine, nephrology, and
rheumatology in Germany (Aachen University Hospital and
Munich University Hospital) and the USA (Georgetown
University Medical Center and Tufts Medical Center). Since
2001, she has been participating in or directing the evidence
review for KDOQI and KDIGO guidelines. As Director of
Guideline Development, Dr Uhlig has a substantial role in
coordinating the ERT. She orchestrates and supervises the
guideline development process and didactic curriculum that
provides Work Group members with formal instruction on
topics related to guideline development. As project director
on individual guidelines, she directs and supervises the
collection, evaluation, grading, and synthesis of evidence and
the drafting and revisions of the final evidence report. She
provides methodological guidance and training to Work
Group members at meetings regarding topic refinement,
key question formulation, data extraction, study assessment,
evidence grading, and recommendation formulation. She
provides nephrology expertise in the interpretation and
review of guideline recommendations and evidence reports.
In this capacity, Dr Uhlig possesses unique knowledge as a
methods expert in evidence synthesis and critical literature
appraisal in the domain of nephrology.
In 2005, she co-chaired the KDIGO Evidence Rating
Group to develop a consensus on grading of KDIGO
guidelines and also co-chaired the KDIGO Consensus
Conference on Guideline Methodology in October 2007.
From 2006 to 2007, she served as Co-Editor of American
Journal of Kidney Diseases. Her teaching and research focus
includes evidence-based medicine, systematic review, clinical
practice guideline development, and critical literature
appraisal. Dr Uhlig lectures on guideline topics and is a co-
instructor of an annual course on meta-analysis in the Master
of Science Program at the Sackler School of Graduate
Biomedical Sciences at Tufts University.
Dr Uhlig reported no relevant financial relationships
Ashish Upadhyay, MD, is Assistant Professor, Renal Section
and Associate Director, Internal Medicine Residency Program
at Boston University School of Medicine, Boston, MA, USA.
Dr Upadhyay was previously Assistant Professor at Tufts
University School of Medicine and staff physician in the
William B Schwartz, MD, Division of Nephrology at Tufts
Medical Center. He joined the ERT in July 2009 and served as
the Assistant Project Director for the KDIGO Management of
Blood Pressure in CKD and Anemia in CKD Guidelines.
Dr Upadhyay coordinated and assisted in the collection, evalua-
tion, grading, and synthesis of evidence, and played a critical
role in the revisions of the final evidence report. He also
provided methodological guidance and training of Work
Group members on topic refinement, key question formula-
tion, data extraction, study assessment, evidence grading, and
recommendation formulation. Dr Upadhyay’s past research
involved studying kidney disease epidemiology in the Framing-
ham Heart Study. He has published in areas ranging from
arterial stiffness in CKD and inflammation in kidney disease to
dialysis complications and epidemiology of hyponatremia.
Dr Upadhyay reported no relevant financial relationships
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Amy Earley, BS, is a project coordinator at the Tufts Center
for Kidney Disease Guideline Development and Implementa-
tion in Boston, MA, USA. She is key in coordinating the
guideline development activities within the ERT, especially
in the development of the evidence reports for all guidelines.
Ms Earley also heads the actual evidence review, which
includes running searches, screening, data extraction, drafting
of tables and methods sections, proofing of guideline drafts
and critical literature appraisals. She participates in the
conduct of research projects at the Center and actively
collaborates with other members of the Center on indepen-
dent research topics and manuscript submissions.
Ms Earley reported no relevant financial relationships
Shana Haynes, MS, DHSc, is a research assistant at the
Tufts Center for Kidney Disease Guideline Development and
Implementation in Boston, MA, USA. She participates in all
aspects of evidence review and guideline development.
She screens abstracts and articles, extracts data, and assists
in the drafting and editing of evidence tables. Dr Haynes
also assists in the development of clinical practice guidelines
and conducts systematic reviews and critical literature
appraisals.
Dr Haynes reported no relevant financial relationships
Jenny Lamont, MS, is a project manager and medical writer
at the Tufts Center for Kidney Disease Guideline Develop-
ment and Implementation in Boston, MA, USA. She
participates in all aspects of evidence review and guideline
development, assists in the preparation of talks and manu-
scripts, and edits KDIGO draft guidelines currently in
progress.
Ms Lamont reported no relevant financial relationships
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